Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Angiodynamics (ANGO) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Angiodynamics (ANGO) over the last 17 years, with Q4 2025 value amounting to $50.9 million.

  • Angiodynamics' Operating Expenses fell 18.04% to $50.9 million in Q4 2025 from the same period last year, while for Nov 2025 it was $200.3 million, marking a year-over-year decrease of 4945.53%. This contributed to the annual value of $197.7 million for FY2025, which is 5078.6% down from last year.
  • Per Angiodynamics' latest filing, its Operating Expenses stood at $50.9 million for Q4 2025, which was down 18.04% from $52.5 million recorded in Q3 2025.
  • In the past 5 years, Angiodynamics' Operating Expenses ranged from a high of $242.4 million in Q1 2024 and a low of $42.3 million during Q1 2021
  • In the last 5 years, Angiodynamics' Operating Expenses had a median value of $51.8 million in 2024 and averaged $61.4 million.
  • As far as peak fluctuations go, Angiodynamics' Operating Expenses surged by 39039.89% in 2024, and later crashed by 7985.64% in 2025.
  • Over the past 5 years, Angiodynamics' Operating Expenses (Quarter) stood at $49.2 million in 2021, then increased by 8.04% to $53.2 million in 2022, then rose by 0.36% to $53.4 million in 2023, then fell by 4.46% to $51.0 million in 2024, then fell by 0.18% to $50.9 million in 2025.
  • Its Operating Expenses was $50.9 million in Q4 2025, compared to $52.5 million in Q3 2025 and $48.0 million in Q2 2025.